Jupiter Asset Management’s Amylyx Pharmaceuticals AMLX Stock Holding History

Jupiter Asset Management’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$4.94M	Sell	274,944 -317,710	-54%	-$4.91M	0.02%	367
2026 Q1	$8.24M	Buy	592,654 +577,080	+3,705%	+$8.12M	0.04%	308
2025 Q4	$188K	Buy	+15,574	New	+$212K	﹤0.01%	401
2024 Q1	–	Sell	-1,060,900	Closed	-$15.6M	–	428
2023 Q4	$15.6M	Buy	1,060,900 +411,164	+63%	+$6.3M	0.15%	171
2023 Q3	$11.9M	Buy	+649,736	New	+$13.7M	0.13%	183

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Jupiter Topco New York $245B AUM

SVCM

Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Asset Management's AMLX Position: Q2 2026 in Review

Jupiter Asset Management reduced its Amylyx Pharmaceuticals (AMLX) stake by 54% in Q2 2026, selling an estimated $4.91M and leaving 274,944 shares worth $4.94M. The position accounts for 0.02% of the portfolio, ranked #367.

Jupiter Asset Management first reported a position in AMLX in Q3 2023 and has held it in 5 quarters since. The position peaked at $15.6M in Q4 2023. 207 funds tracked by Wall St. Rank hold AMLX as of Q2 2026.

Jupiter Asset Management held 274,944 shares of Amylyx Pharmaceuticals worth $4.94M as of Q2 2026.
Jupiter Asset Management sold 317,710 Amylyx Pharmaceuticals shares in Q2 2026, an estimated $4.91M.
Amylyx Pharmaceuticals made up 0.02% of Jupiter Asset Management's portfolio in Q2 2026, its #367 holding.
Jupiter Asset Management first reported a position in Amylyx Pharmaceuticals in Q3 2023 and has held it in 5 quarters since.
Jupiter Asset Management's Amylyx Pharmaceuticals position peaked at $15.6M in Q4 2023.
207 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q2 2026.

Based on Jupiter Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.